Does larazotide let people with celiac disease eat gluten?

No. In every trial it was studied only as an add-on to a continued gluten-free diet, and even then benefits were modest. It is not a license to consume gluten.

Why did the lowest dose work best?

In the 342-patient trial the 0.5 mg dose met the symptom endpoint while higher doses did not. The reason for this non-linear, dose-paradoxical pattern is not fully understood and is a limitation of the evidence.

Is the zonulin mechanism proven?

No. While larazotide is often called a zonulin antagonist, a 2021 analysis in Gut argued its effects are not actually explained by zonulin, so the mechanism remains debated.

Is larazotide safe to buy and self-administer?

It is not an approved medicine, so any product sold to consumers is unregulated and its identity, purity, and safety cannot be assured. Self-administration is not appropriate; larazotide has only been evaluated in supervised clinical trials.

Research chemical — not approvedaka Larazotide acetate, AT-1001, INN-202

Larazotide — Complete Research Guide (2026)

Last updated 2026-06-25

TL;DR

An investigational peptide studied as a tight-junction regulator for celiac disease in human clinical trials; not approved.

What is Larazotide?

Larazotide acetate (AT-1001) is an investigational, orally administered eight-amino-acid peptide that acts locally in the gut as a tight-junction regulator, studied as an adjunct to the gluten-free diet in celiac disease. It is NOT an approved drug in any jurisdiction and remains research/investigational only.

Evidence includes several small-to-mid-size phase 2 randomized controlled trials in humans; a phase 3 program (CeD-LARA) has been conducted, but no regulator has approved it.

How does Larazotide work?

Larazotide is proposed to act as a zonulin antagonist that restricts gluten-triggered opening of intestinal epithelial tight junctions, thereby limiting paracellular passage of gluten peptides; some authors also implicate inhibition of myosin light-chain kinase.

The zonulin-antagonist explanation has itself been questioned in the literature. [INFOGRAPHIC: Larazotide tight-junction regulation in the gut]

What does the research say about Larazotide?

In a 342-patient phase 2 RCT, only the lowest dose (0.5 mg three times daily) significantly reduced persistent gastrointestinal symptoms versus placebo in celiac patients already on a gluten-free diet; higher doses did not, so the effect was modest and dose-paradoxical. ^[4]
In an 86-patient gluten-challenge RCT, lower doses of larazotide limited gluten-induced worsening of symptoms, but the drug did not significantly change the lactulose-to-mannitol intestinal-permeability ratio (its intended pharmacodynamic marker). ^[2]
First-in-human proof-of-concept work found single doses of AT-1001 were safe and well tolerated and attenuated gluten-induced permeability and symptom signals, establishing rationale for later trials (small early-phase human study). ^[1]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study — Paterson BM et al., Aliment Pharmacol Ther 2007. (early-phase human proof-of-concept)
[2] A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge — Leffler DA et al., Am J Gastroenterol 2012. (RCT, n=86 (gluten challenge))
[3] Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study — Kelly CP et al., Aliment Pharmacol Ther 2013. (RCT (gluten challenge))
[4] Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial — Leffler DA et al., Gastroenterology 2015. (phase 2 RCT, n=342)
[5] Larazotide acetate: a pharmacological peptide approach to tight junction regulation — Slifer ZM et al., Am J Physiol Gastrointest Liver Physiol 2021. (review)
[6] Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications — Sollid LM et al., Gut 2021. (mechanistic analysis / commentary)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: published trials evaluated oral doses in the 0.5-2 mg range taken three times daily before meals, and, counterintuitively, the lowest 0.5 mg dose performed best while higher doses did not.

No dosing guidance is provided here; larazotide is not an approved medicine and any use outside a supervised clinical trial is inappropriate.

Side effects & safety profile

Across the published phase 2 trials larazotide was generally well tolerated, with adverse events broadly similar to placebo; because it is minimally absorbed and acts locally in the gut, systemic exposure is low.

However, it is investigational and unapproved, long-term safety is not established, and it should not be regarded as a treatment.

Its proposed zonulin-antagonist mechanism has been directly challenged in peer review, so even the pharmacology is not settled.

Stacking & combinations

Larazotide has only ever been studied as an adjunct to a continued gluten-free diet, not as a replacement for it and not in combination with other peptides.

Finding Larazotide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

No. It is investigational only. It has been through multiple phase 2 trials and a phase 3 program, but no regulator (FDA, EMA, or others) has approved it as of this writing.

References

[1] The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study — Paterson BM et al., Aliment Pharmacol Ther 2007. PMID: 17697209. View sourceStudy: early-phase human proof-of-conceptSingle doses of AT-1001 were safe and well tolerated and reduced gluten-induced intestinal permeability and symptom signals in celiac subjects.
[2] A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge — Leffler DA et al., Am J Gastroenterol 2012. PMID: 22825365. View sourceStudy: RCT, n=86 (gluten challenge)Lower doses limited gluten-induced symptom worsening, but larazotide did not significantly change the lactulose/mannitol permeability ratio.
[3] Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study — Kelly CP et al., Aliment Pharmacol Ther 2013. PMID: 23163616. View sourceStudy: RCT (gluten challenge)Larazotide reduced gluten-challenge-induced signs and symptoms relative to placebo.
[4] Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial — Leffler DA et al., Gastroenterology 2015. PMID: 25683116. View sourceStudy: phase 2 RCT, n=342Only the 0.5 mg three-times-daily dose significantly reduced persistent GI symptoms versus placebo in patients on a gluten-free diet.
[5] Larazotide acetate: a pharmacological peptide approach to tight junction regulation — Slifer ZM et al., Am J Physiol Gastrointest Liver Physiol 2021. PMID: 33881350. View sourceStudy: reviewSummarizes larazotide's proposed tight-junction/zonulin-antagonist mechanism and its status in phase 3 development for celiac disease.
[6] Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications — Sollid LM et al., Gut 2021. PMID: 33443022. View sourceStudy: mechanistic analysis / commentaryArgues AT-1001's activity is not explained by zonulin antagonism, questioning the widely cited proposed mechanism.

Related peptides

KPVHealing & Recovery BPC-157Healing & Recovery

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.